奈米药物市场－全球产业规模、份额、趋势、机会和预测，按形态、应用、地区和竞争格局划分，2020-2030年预测

2024年全球奈米药物市场规模为596.8亿美元，预计到2030年将以9.80%的复合年增长率增长至1045.8亿美元。奈米药物是一类利用奈米技术增强治疗药物传递、标靶性和疗效的药物，通常以奈米级（1至100奈米）製备，以提高药物的溶解度、稳定性和生物利用度。市场扩张的主要驱动因素是慢性疾病盛行率的不断上升，对标靶性和更有效的治疗方案的需求日益增长，以及政府和私人机构对再生医学和奈米技术药物研发投入的不断增加。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球奈米药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依形态分类（脂质体、聚合物胶束、固体脂质奈米颗粒、微乳液、奈米乳液、奈米悬浮液、其他）
  • 依应用领域（临床肿瘤学、传染病学、心血管疾病）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美奈米药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲奈米药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太纳米药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲奈米药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲奈米药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球奈米药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Abbott Laboratories Inc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Johnson & Johnson (J&J)
• Gilead Sciences, Inc.
• AstraZeneca plc
• Celgene Corporation

第十六章：策略建议

第17章调查会社について・免责事项

The Global Nanopharmaceuticals Market, valued at USD 59.68 Billion in 2024, is projected to experience a CAGR of 9.80% to reach USD 104.58 Billion by 2030. Nanopharmaceuticals are a class of pharmaceutical drugs leveraging nanotechnology for enhanced therapeutic agent delivery, targeting, and efficacy, typically formulated at the nanoscale (1 to 100 nanometers) to improve solubility, stability, and bioavailability. The market's expansion is primarily driven by the increasing prevalence of chronic diseases demanding targeted and more effective treatment options, coupled with growing government and private funding in regenerative medicine and nanotechnology-based drug development.

Key Market Drivers

The rising prevalence of chronic diseases represents a profound market driver, fueling an urgent demand for advanced therapeutic solutions that surpass the limitations of conventional treatments. Global health challenges posed by conditions such as cancer, cardiovascular ailments, and neurological disorders necessitate therapies offering enhanced efficacy and reduced systemic burden. Nanopharmaceuticals directly address this need through targeted delivery and improved bioavailability, promising better patient outcomes.

Key Market Challenges

The nanopharmaceuticals market faces significant impediment from the high investments required for drug development and the complexities surrounding regulatory approvals for novel nanoscale therapeutics. These factors collectively contribute to prolonged development timelines and substantially increased costs, directly impeding widespread market adoption and commercialization. Developing nanopharmaceuticals demands extensive research and development to understand novel material properties, ensure safety, and demonstrate efficacy at the nanoscale.

Key Market Trends

The focus on personalized nanomedicine is driving advancements by tailoring treatments to individual patient profiles, moving beyond a one-size-fits-all approach. This customization allows for optimized therapeutic effects and reduced adverse reactions, particularly critical for complex diseases. For instance, according to Precision Nanomedicine for Cancer: Innovations, Strategies, and Translational Challenges, published October 2025, the formulation of anti-EpCAM aptamers has risen as an advanced tactic for precise conveyance of therapeutics to malignant tissues, demonstrating significant potential in preliminary research and clinical trials. This capability enhances treatment efficacy and patient outcomes by ensuring therapeutic agents are delivered with high specificity.

Key Market Players

• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Abbott Laboratories Inc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Johnson & Johnson (J&J)
• Gilead Sciences, Inc.
• AstraZeneca plc
• Celgene Corporation

Report Scope:

In this report, the Global Nanopharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nanopharmaceuticals Market, By Form:

• Liposomes
• Polymeric Micelles
• Solid Lipid Nanoparticles
• Microemulsion
• Nanoemulsion
• Nanosuspension
• Others

Nanopharmaceuticals Market, By Application:

• Clinical Oncology
• Infectious Diseases
• Cardiovascular Diseases

Nanopharmaceuticals Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nanopharmaceuticals Market.

Available Customizations:

Global Nanopharmaceuticals Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nanopharmaceuticals Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Form (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Nanosuspension, Others)
  • 5.2.2. By Application (Clinical Oncology, Infectious Diseases, Cardiovascular Diseases)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Nanopharmaceuticals Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Form
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nanopharmaceuticals Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Form
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Nanopharmaceuticals Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Form
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Nanopharmaceuticals Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Form
      • 6.3.3.2.2. By Application

7. Europe Nanopharmaceuticals Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Form
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nanopharmaceuticals Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Form
      • 7.3.1.2.2. By Application
  • 7.3.2. France Nanopharmaceuticals Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Form
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Nanopharmaceuticals Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Form
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Nanopharmaceuticals Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Form
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Nanopharmaceuticals Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Form
      • 7.3.5.2.2. By Application

8. Asia Pacific Nanopharmaceuticals Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Form
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nanopharmaceuticals Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Form
      • 8.3.1.2.2. By Application
  • 8.3.2. India Nanopharmaceuticals Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Form
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Nanopharmaceuticals Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Form
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Nanopharmaceuticals Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Form
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Nanopharmaceuticals Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Form
      • 8.3.5.2.2. By Application

9. Middle East & Africa Nanopharmaceuticals Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Form
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nanopharmaceuticals Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Form
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Nanopharmaceuticals Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Form
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Nanopharmaceuticals Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Form
      • 9.3.3.2.2. By Application

10. South America Nanopharmaceuticals Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Form
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nanopharmaceuticals Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Form
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Nanopharmaceuticals Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Form
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Nanopharmaceuticals Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Form
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nanopharmaceuticals Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck & Co., Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Novartis AG
• 15.4. Abbott Laboratories Inc.
• 15.5. GlaxoSmithKline plc
• 15.6. Eli Lilly and Company
• 15.7. Johnson & Johnson (J&J)
• 15.8. Gilead Sciences, Inc.
• 15.9. AstraZeneca plc
• 15.10. Celgene Corporation

16. Strategic Recommendations

17. About Us & Disclaimer